Clinical trial
Infliximab in High Need Versus Low Need Psoriasis Patients: The IHELP Study…
NCT00254982 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00254982 |
|---|---|
| Title | Infliximab in High Need Versus Low Need Psoriasis Patients: The IHELP Study (Study P04320)(COMPLETED) |
| Official title | An Open-Label Study to Determine Equivalence in Efficacy, Organ Safety and Systemic Tolerability Between Infliximab in GROUP I ("High Need") and GROUP II ("Low Need") Patients Suffering From Chronic Plaque Psoriasis (Psoriasis Vulgaris) |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Collaborators | Essex Pharma GmbH Industry Centocor, Inc. |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Biological |
| Interventions | Infliximab |
| Enrollment | 593 |
| Start date | Aug 1, 2005 |
| Primary completion | Sep 1, 2006 |
| Completion | Sep 1, 2006 |
| First posted | Nov 17, 2005 |
| Last update posted | Oct 12, 2015 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: